HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Redefining biomarkers in heart failure.

Abstract
Heart failure (HF) is the end result of many different cardiac and non-cardiac abnormalities leading to a complex clinical entity. In this view, the use of biomarkers in HF should be deeply reconsidered; indeed, the same biomarker may carry a different significance in patients with preserved or reduced EF. The aim of this review is to reconsider the role of biomarkers in HF, based on the different clinical characteristics of this syndrome. The role of cardiac and non-cardiac biomarkers will be reviewed with respect of the different clinical manifestations of this syndrome.
AuthorsMichele Correale, Ilenia Monaco, Natale Daniele Brunetti, Matteo Di Biase, Marco Metra, Savina Nodari, Javed Butler, Mihi Gheorghiade, Master Program Students on Drug Development for Heart Failure
JournalHeart failure reviews (Heart Fail Rev) Vol. 23 Issue 2 Pg. 237-253 (03 2018) ISSN: 1573-7322 [Electronic] United States
PMID29511896 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers
Topics
  • Biomarkers (blood)
  • Heart Failure (blood, physiopathology)
  • Humans
  • Stroke Volume (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: